Merck KGaA Highlights First In Class Five For 2025 Market Boom

 
• By Ayisha Sharma

From BTK inhibitors in multiple sclerosis to candidates aiding cancer cell death, Merck KGaA is focusing on its first-in-class pipeline which it expects to make a significant impact from 2025.  

Merck Has Ambitious Plans For Yearly Regulatory Submissions • Source: Alamy

More from Business

More from Scrip